MITPF Quote, Financials, Valuation and Earnings

MDxHealth SA has a net margin of -- compared to Mithra Pharmaceuticals SA's net margin of -27.65%. Mithra Pharmaceuticals SA's return on equity of -- beat MDxHealth SA's return on equity of -395.93%.

Mithra Pharmaceuticals SA has a consensus price target of --, signalling downside risk potential of --. On the other hand MDxHealth SA has an analysts' consensus of $6.0400 which suggests that it could grow by 277.5%. Given that MDxHealth SA has higher upside potential than Mithra Pharmaceuticals SA, analysts believe MDxHealth SA is more attractive than Mithra Pharmaceuticals SA.

Mithra Pharmaceuticals SA has a beta of 0.342, which suggesting that the stock is 65.796% less volatile than S&P 500. In comparison MDxHealth SA has a beta of -458,274.035, suggesting its less volatile than the S&P 500 by 45827503.54%.

Mithra Pharmaceuticals SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MDxHealth SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mithra Pharmaceuticals SA pays -- of its earnings as a dividend. MDxHealth SA pays out -- of its earnings as a dividend.

Mithra Pharmaceuticals SA quarterly revenues are --, which are smaller than MDxHealth SA quarterly revenues of $24.7M. Mithra Pharmaceuticals SA's net income of -- is lower than MDxHealth SA's net income of -$6.8M. Notably, Mithra Pharmaceuticals SA's price-to-earnings ratio is -- while MDxHealth SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mithra Pharmaceuticals SA is -- versus 0.67x for MDxHealth SA. Usually stocks with elevated PS ratios are considered overvalued.

Nyxoah SA has a net margin of -- compared to Mithra Pharmaceuticals SA's net margin of -1357.8%. Mithra Pharmaceuticals SA's return on equity of -- beat Nyxoah SA's return on equity of -56.62%.

Mithra Pharmaceuticals SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Nyxoah SA has an analysts' consensus of $15.08 which suggests that it could grow by 152.13%. Given that Nyxoah SA has higher upside potential than Mithra Pharmaceuticals SA, analysts believe Nyxoah SA is more attractive than Mithra Pharmaceuticals SA.

Mithra Pharmaceuticals SA has a beta of 0.342, which suggesting that the stock is 65.796% less volatile than S&P 500. In comparison Nyxoah SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Mithra Pharmaceuticals SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nyxoah SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mithra Pharmaceuticals SA pays -- of its earnings as a dividend. Nyxoah SA pays out -- of its earnings as a dividend.

Mithra Pharmaceuticals SA quarterly revenues are --, which are smaller than Nyxoah SA quarterly revenues of $1.3M. Mithra Pharmaceuticals SA's net income of -- is lower than Nyxoah SA's net income of -$18.3M. Notably, Mithra Pharmaceuticals SA's price-to-earnings ratio is -- while Nyxoah SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mithra Pharmaceuticals SA is -- versus 39.97x for Nyxoah SA. Usually stocks with elevated PS ratios are considered overvalued.

Remedent has a net margin of -- compared to Mithra Pharmaceuticals SA's net margin of --. Mithra Pharmaceuticals SA's return on equity of -- beat Remedent's return on equity of --.

Mithra Pharmaceuticals SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Remedent has an analysts' consensus of -- which suggests that it could fall by --. Given that Mithra Pharmaceuticals SA has higher upside potential than Remedent, analysts believe Mithra Pharmaceuticals SA is more attractive than Remedent.

Mithra Pharmaceuticals SA has a beta of 0.342, which suggesting that the stock is 65.796% less volatile than S&P 500. In comparison Remedent has a beta of -0.150, suggesting its less volatile than the S&P 500 by 115.037%.

Mithra Pharmaceuticals SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Remedent offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mithra Pharmaceuticals SA pays -- of its earnings as a dividend. Remedent pays out -- of its earnings as a dividend.

Mithra Pharmaceuticals SA quarterly revenues are --, which are smaller than Remedent quarterly revenues of --. Mithra Pharmaceuticals SA's net income of -- is lower than Remedent's net income of --. Notably, Mithra Pharmaceuticals SA's price-to-earnings ratio is -- while Remedent's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mithra Pharmaceuticals SA is -- versus 0.48x for Remedent. Usually stocks with elevated PS ratios are considered overvalued.

UCB SA has a net margin of -- compared to Mithra Pharmaceuticals SA's net margin of --. Mithra Pharmaceuticals SA's return on equity of -- beat UCB SA's return on equity of 11.39%.

Mithra Pharmaceuticals SA has a consensus price target of --, signalling downside risk potential of --. On the other hand UCB SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Mithra Pharmaceuticals SA has higher upside potential than UCB SA, analysts believe Mithra Pharmaceuticals SA is more attractive than UCB SA.

Mithra Pharmaceuticals SA has a beta of 0.342, which suggesting that the stock is 65.796% less volatile than S&P 500. In comparison UCB SA has a beta of 0.758, suggesting its less volatile than the S&P 500 by 24.243%.

Mithra Pharmaceuticals SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UCB SA offers a yield of 0.91% to investors and pays a quarterly dividend of $0.72 per share. Mithra Pharmaceuticals SA pays -- of its earnings as a dividend. UCB SA pays out 24.32% of its earnings as a dividend. UCB SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Mithra Pharmaceuticals SA quarterly revenues are --, which are smaller than UCB SA quarterly revenues of --. Mithra Pharmaceuticals SA's net income of -- is lower than UCB SA's net income of --. Notably, Mithra Pharmaceuticals SA's price-to-earnings ratio is -- while UCB SA's PE ratio is 27.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mithra Pharmaceuticals SA is -- versus 4.73x for UCB SA. Usually stocks with elevated PS ratios are considered overvalued.